Leadership and Board of Directors

Fortunato Ron Rocca has served as our President and Chief Executive Officer and as a member of our board of directors since December 2011. From 2005 to October 2011, Mr. Rocca served as Vice President, Sales and Marketing, and as General Manager, at Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company which was acquired by Nestlé© SA in 2011, where he was responsible for leading the commercial organization, strategic planning and implementing projects designed to maximize brand sales. Prior to Prometheus, Mr. Rocca was the General Manager of Alpharma Inc., a specialty pharmaceutical company. Earlier in his career, Mr. Rocca served in senior sales and marketing management positions for Elan Pharmaceuticals, Inc., a neuroscience-focused biotechnology company. Mr. Rocca received a B.A. in Marketing and Personnel Management from Towson University.

Kamal Adawi has served as our Chief Financial Officer since June 2017. Kamal previously held the positions of Chief Financial Officer, Corporate Secretary and Treasurer at Pathway Genomics, a global genetic testing company. Prior to joining Pathway Genomics, Kamal served as the Director of Financial Planning and Analysis at Exagen. Kamal previously managed the finance departments for GenMark Dx and Digirad, both publicly traded diagnostic companies. He also served in various capacities in the finance and accounting departments at Becton, Dickinson and Co., a global medical technology company. Kamal’s education includes three degrees in the field of business. He earned a bachelor’s degree from Michigan State University with a major in finance, an MBA from Oakland University with a focus on management and a master’s degree in finance from San Diego State University.

Debra Jeske Zack, M.D., Ph.D., has served as Chief Medical Officer since March 2020. Dr. Zack is a board-certified rheumatologist with broad experience as a strategic biopharmaceutical executive in the development of therapeutics for autoimmune disease and will oversee the overall strategy and execution of the company’s clinical development plans. She has extensive experience leading research, clinical development and medical affairs teams focusing on autoimmune disorders. Prior to joining Exagen, Dr. Zack served as Vice President, Clinical Development at Xencor, Inc.; Executive Director, Medical Scientific Leader, Biotherapeutics Development Unit at Novartis; and various positions in basic research, clinical development and medical affairs at Amgen. She was an associate professor treating rheumatology patients for 10 years at UCLA prior to joining industry. She received her undergraduate degree from Texas Christian University and her M.D. and Ph.D. from the University of Texas Southwestern in Dallas before completing her residency and rheumatology fellowship at the UCLA School of Medicine.

Mark Hazeltine has served as our Chief Operating Officer since March 2021 and served in multiple key leadership roles including General Manager, Senior Vice President of Finance and Corporate Development, VP of Finance, and Sr. Director of Financial Planning & Analysis since 2015. Prior to joining Exagen, Mr. Hazeltine served as Director of Financial Planning and Analysis and Director of Financial Business Processes at CareFusion, a medical technology corporation. Mr. Hazeltine also worked in multiple management roles at multinational organizations including Kyocera and Qualcomm. Mr. Hazeltine received his Bachelor of Business Administration degree from the University of San Diego and Master of Business Administration degree from the Marshall School of Business at the University of Southern California.

Dr. Kammesheidt has deep experience as a strategic biotech executive in the development of novel testing solutions and will be responsible for the oversight and execution of the company’s research and development plans. Over the course of her career, she has built multiple successful diagnostics companies with direct responsibility for all R&D activities. Prior to joining Exagen, Dr. Kammesheidt served as Chief Scientific Officer at Ambry Genetics and Pathway Genomics, and also held R&D positions at Agendia Inc. and Purdue Pharma. She received her undergraduate degree and Ph.D. from the University of California, Irvine, and conducted her post-doctoral training at the University of California, San Diego.

Dr. Ming-Chou Lee has served as Chief Technology Officer since August 2021. Dr. Lee has extensive experience in IVD and CLIA LDT product development. He has successfully led the development of numerous FDA cleared/CE marked diagnostic products currently on the market. Prior to joining Exagen, Dr. Lee served as VP of Product Development at PrimeraDx of Qiagen, MDx Health, and Metabiomics, as Molecular R&D Director at Focus Diagnostics of Quest Diagnostics and Sr. Director of Assay Development at ArcherDx. Dr. Lee received his Ph.D. from the University of Alabama in Birmingham and did his post-doctoral training at SmithKline & French.

John Wegener has served as our Vice President, Sales and Managed Markets since November 2013. Prior to joining Exagen, Mr. Wegener served in various capacities with Prometheus Laboratories from 1999 to October 2013, including as the National Director, Managed Care and a Regional Sales Director. During his time at Prometheus, Mr. Wegener launched five new diagnostic tests and managed diagnostic channels with national general reference laboratories. Prior to Prometheus, Mr. Wegener worked in sales for Novartis. Mr. Wegener holds a B.S. in Business from the University of Arizona.

Brian Birk has served as a member of our board of directors since June 2008. In 2006, Mr. Birk co-founded Sun Mountain Capital, a boutique private equity firm focused on the Southwest and Rocky Mountain regions which currently manages direct investment funds and funds of funds vehicles. Prior to forming Sun Mountain Capital, Mr. Birk was a Vice President and Director of Private Equity at Fort Washington Capital Partners, a professional investment management services company. Mr. Birk was also a senior executive at MetaWeb Technologies, Inc., a technology and web development company acquired by Google Inc. in 2010, the vice president of technology commercialization at Applied Minds, LLC, a technology consulting company, and the president of a division at BiosGroup Inc., a company which commercialized complex science software. In addition, Mr. Birk held a senior manager position at the Boston Consulting Group, Inc., a global management consulting firm, and finance manager positions at General Electric Company and GE Capital Corporation. Mr. Birk is currently a member of the board of directors of several private companies, including Aspen Avionics, Inc., an aircraft avionics manufacturer, and American Clay Enterprises, LLC, a plaster manufacturing and sales company. Mr. Birk received a B.S. in Economics from Carleton College and an M.B.A. from Northwestern University's Kellogg School of Management.

Fortunato Ron Rocca has served as our President and Chief Executive Officer since October 2011 and as a member of our board of directors since December 2011. From 2005 to October 2011, Mr. Rocca served as Vice President, Sales and Marketing, and as General Manager, at Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company which was acquired by Nestlé© SA in 2011, where he was responsible for leading the commercial organization, strategic planning and implementing projects designed to maximize brand sales. Prior to Prometheus, Mr. Rocca was the General Manager of Alpharma Inc., a specialty pharmaceutical company. Earlier in his career, Mr. Rocca served in senior sales and marketing management positions for Elan Pharmaceuticals, Inc., a neuroscience-focused biotechnology company. Mr. Rocca received a B.A. in Marketing and Personnel Management from Towson University.

Ana Hooker has served as the Senior Vice President, Operations of Exact Sciences Corporation, a molecular diagnostics company, since July 2015. Ms. Hooker joined Exact Sciences Corporation in March 2013 with a focus on opening a new clinical laboratory in preparation for the launch of Cologuard. Prior to joining Exact Sciences Corporation, Ms. Hooker was at ARUP Laboratories for 15 years. While at ARUP Laboratories, Ms. Hooker held positions of increasing responsibility, including Group Manager for the Divisions of Oncology and Genetics, Technical Supervisor of the University of Utah Hospital Clinical Laboratories, Vice President, Division Manager for genetics and Senior Vice President, Division Manager for anatomic pathology, oncology and genetics. Ms. Hooker currently serves on the boards of Big Brothers, Big Sisters of Dane County and the Overture Center for the Arts. Ms. Hooker is also a member of the Latino Professional Association (LPA), Clinical Laboratory Management Association (CLMA), Association of Molecular Pathology (AMP), and the American Society of Clinical Laboratory Science (ASCLS). Ms. Hooker earned a Bachelor of Science from Kansas State University, a medical technologist degree from Hays Pathology Laboratories, and an M.B.A. from Westminster College.

Ms. Johnson has a distinguished career in healthcare performing various roles integral to corporate growth. She is currently the Chief Operating Officer of Reneo Pharmaceuticals where she is responsible for day-to-day operations, and was instrumental in setting up the company’s UK corporate entity. Ms. Johnson was previously the Interim Chief Operating Officer of AmpliPhi Biosciences Corporation from September 2014 to January 2017, and a member of its board of directors from May 2014 until its merger with C3J Therapeutics (Armata Pharmaceuticals) in May 2019. From 2005 to January 2014, Ms. Johnson served as a venture partner at ProQuest Investments, a venture capital firm. From 2006 to January 2014, Ms. Johnson served as the President and Chief Executive Officer of Aires Pharmaceuticals, a ProQuest portfolio company, until its sale to MAST Therapeutics in 2014. Prior to joining ProQuest, she held senior business and corporate development positions at Salmedix Inc., WomenFirst Healthcare, Prizm Pharmaceuticals (Selective Genetics Inc.), Cytel Corp., Synbiotics Corp., and Murex Corp. (Cambridge U.K.). Additionally, Ms. Johnson served as Assistant Director with the Center for Devices and Radiological Health at the U.S. Food and Drug Administration. Ms. Johnson is also presently on the Board of Directors of MorphoSys AG, one of the oldest biotechnology companies in Europe. Ms. Johnson received an M.B.A. from Loyola University Maryland, her M.S. in Clinical Microbiology from the Hahnemann Medical School, and her B.S. in Microbiology from the University of Maryland.

Tina S. Nova, Ph.D. has extensive experience growing dynamic commercial organizations in new markets within the molecular diagnostics field. Since August 2018, she has served as president and chief executive officer of Decipher Biosciences, Inc., a diagnostics company focused on urologic cancers. Previously Dr. Nova was president and chief executive officer of Molecular Stethoscope, Inc., and served as senior vice president and general manager of Illumina’s oncology business unit. Dr. Nova was a co-founder of Genoptix, a medical laboratory diagnostics company, and served as its president and chief executive officer from 2000 to 2014. Genoptix was acquired by Novartis AG in 2011. Dr. Nova was co-founder of Nanogen, a provider of molecular diagnostic tests, and served as its chief operating officer and president from 1994 to 2000. She previously served as chief operating officer of Selective Genetics, and held various positions with Ligand Pharmaceuticals and Hybritech. Dr. Nova serves as the chair of the board of directors for Arena Pharmaceuticals and as a member of the board of directors of Veracyte, a diagnostics company. Dr. Nova received a bachelor’s degree in biological sciences from the University of California, Irvine, and a doctorate in biochemistry from the University of California, Riverside.

Ebetuel Pallares, Ph.D. has served as a member of our board of directors since October 2012. Dr. Pallares founded Joseph Advisory Services, LLC, a strategic consulting firm, in 2006, and has served as its manager since that time. In June 2009, he co-founded Cottonwood Capital Partners, the general partner of Cottonwood Technology Fund, a seed and early-stage venture fund with headquarters in El Paso, Texas, and he has served as its managing partner since that time. Dr. Pallares also serves on several corporate and non-profit boards, as an advisor to the UT Horizon Fund, the venture capital investment fund of the University of Texas system, as an Investor in Residence for New Mexico State University's Arrowhead Center and on the limited partnership advisory committee for several venture funds. He received a B.A. in economics from Brandeis University, an M.B.A. from The University of Texas at El Paso, or UTEP, and a Ph.D. in International Business from UTEP.

Bruce Robertson, Ph.D. is a Managing Director of H.I.G. BioHealth Partners, the healthcare affiliate of H.I.G. Capital, a private equity firm with over $31 billion under management. Dr. Robertson has been active in the life sciences sector for more than 30 years. Prior to joining H.I.G., he served most recently as Managing Director at Toucan Capital, a venture capital fund focusing on healthcare investments. Prior to his private equity career, Dr. Robertson was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN's partnering and M&A strategies. Dr. Robertson started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices. Dr. Robertson currently serves on the boards of Apollo Endosurgery, RxSight, CardioFocus, Clarus Therapeutics, Iconic Therapeutics, and Intact Vascular. Dr. Robertson holds a BSE in Chemical Engineering and BA in Mathematics from the University of Pennsylvania, a Ph.D. in Chemical Engineering from the University of Delaware, and an MBA with High Distinction from Harvard Business School.

Mr. Stokes has served as the Chief Financial Officer of Castle Biosciences, Inc., a skin cancer diagnostics company, since December 2017. From January 2017 to December 2017, Mr. Stokes served as Chief Financial Officer of Hammock Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of women's health and urology products. From May 2011 to December 2016, Mr. Stokes served as a Managing Director of Leerink Swann (now SVB Leerink). Mr. Stokes also held positions as a Managing Director at Robert W. Baird & Co. Incorporated and Wachovia Securities, LLC. While at SVB Leerink and Robert W. Baird & Co., Mr. Stokes led life sciences, tools and diagnostics sector investment banking efforts and managed financings and mergers and acquisitions transactions. Mr. Stokes obtained a Bachelor of Science in Business Administration, Master of Business Administration and Doctor of Jurisprudence, all from the University of North Carolina at Chapel Hill.

Jim Tullis founded Tullis Health Investors (“THI” or “Tullis-Dickerson & Co., Inc.”) in 1986 and has a career of over 40 years in health care investing. Prior to establishing Tullis Health Investors, Jim was a Senior Vice President of E.F. Hutton & Co. (1983-1986) and a Principal at Morgan Stanley & Co. (1974-1983), where he led health care investment research and, later, healthcare investment banking. During his tenure at Morgan Stanley, he received recognition 14 times on the Institutional Investor All-Star list of Wall Street’s top securities analysts and listing as a top home run hitter. He was twice named #1 Drug Analyst and was featured on the Wall Street Week television program. From 1972-1974, Jim was Vice President of Putnam Funds researching health care industry equities. Under Jim’s direction, THI has managed several venture capital funds investing into the health care industry. Winning portfolio companies of those funds include Adams Respiratory and Sirion (with innovative concepts in pharmaceuticals); Synageva and BioRexis (biotechnology); Atritech and Vidacare (medical devices); PSS World Medical and Impulse Monitoring (medical services); and Intelliclaim and QuadraMed (health care information technology). Jim is a graduate of Stanford University and earned an MBA from Harvard Business School. He currently sits on the Boards of the Lord Abbett family of mutual funds, Crane Corporation (NYSE: CR), SupplyPro, Inc., Exagen Inc., and electroCore, LLC.